ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1PFE | PFIZER INC | Healthcare | $164.33B | 18.01% |
2CVS | CVS HEALTH CORP | Healthcare | $114.88B | 12.59% |
3ELV | ELEVANCE HEALTH INC | Healthcare | $92.88B | 10.18% |
4CI | CIGNA GROUP | Healthcare | $78.07B | 8.55% |
5COR | CENCORA INC | Healthcare | $66.67B | 7.31% |
6HUM | HUMANA INC | Healthcare | $53.29B | 5.84% |
7GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $37.00B | 4.05% |
8CNC | CENTENE CORP | Healthcare | $34.79B | 3.81% |
9VTRS | VIATRIS INC | Healthcare | $23.70B | 2.60% |
10THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 2.50% |
11ZBH | ZIMMER BIOMET HOLDINGS INC | Healthcare | $19.79B | 2.17% |
12BAX | BAXTER INTERNATIONAL INC | Healthcare | $13.32B | 1.46% |
13ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $13.25B | 1.45% |
14COO | COOPER COMPANIES INC | Healthcare | $11.83B | 1.30% |
15UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $11.18B | 1.22% |
16BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $10.98B | 1.20% |
17MOH | MOLINA HEALTHCARE INC | Healthcare | $10.95B | 1.20% |
18DVA | DAVITA INC | Healthcare | $10.95B | 1.20% |
19BIO | BIO-RAD LABORATORIES INC | Healthcare | $9.96B | 1.09% |
20OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 1.09% |
21HSIC | HENRY SCHEIN INC | Healthcare | $9.52B | 1.04% |
22BLCO | BAUSCH & LOMB CORP | Healthcare | $7.56B | 0.83% |
23TFX | TELEFLEX INC | Healthcare | $6.07B | 0.67% |
24WAY | WAYSTAR HOLDING CORP | Healthcare | $5.41B | 0.59% |
25NVST | ENVISTA HOLDINGS CORP | Healthcare | $3.95B | 0.43% |
26OGN | ORGANON & CO | Healthcare | $3.65B | 0.40% |
27ACHC | ACADIA HEALTHCARE COMPANY INC | Healthcare | $3.52B | 0.39% |
28SGRY | SURGERY PARTNERS INC | Healthcare | $3.48B | 0.38% |
29BHC | BAUSCH HEALTH COMPANIES INC | Healthcare | $3.09B | 0.34% |
30ARDT | ARDENT HEALTH INC | Healthcare | $2.49B | 0.27% |
31NEOG | NEOGEN CORP | Healthcare | $2.44B | 0.27% |
32PRGO | PERRIGO CO PLC | Healthcare | $2.25B | 0.25% |
33PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.15B | 0.24% |
34BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $2.14B | 0.23% |
35FTRE | FORTREA HOLDINGS INC | Healthcare | $1.94B | 0.21% |
36AZTA | AZENTA INC | Healthcare | $1.92B | 0.21% |
37TRLV | TRULIEVE CANNABIS CORP | Healthcare | $1.90B | 0.21% |
38XRAY | DENTSPLY SIRONA INC | Healthcare | $1.83B | 0.20% |
39ASTH | ASTRANA HEALTH INC | Healthcare | $1.77B | 0.19% |
40SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.72B | 0.19% |
41SNDA | SONIDA SENIOR LIVING INC | Healthcare | $1.63B | 0.18% |
42ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.62B | 0.18% |
43OMCL | OMNICELL INC | Healthcare | $1.61B | 0.18% |
44ENOV | ENOVIS CORP | Healthcare | $1.59B | 0.17% |
45TDOC | TELADOC HEALTH INC | Healthcare | $1.58B | 0.17% |
46ALHC | ALIGNMENT HEALTHCARE INC | Healthcare | $1.57B | 0.17% |
47CNMD | CONMED CORP | Healthcare | $1.50B | 0.16% |
48AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.16% |
49PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.16% |
50LMRI | LUMEXA IMAGING HOLDINGS INC | Healthcare | $1.44B | 0.16% |
51INVA | INNOVIVA INC | Healthcare | $1.35B | 0.15% |
52AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $1.23B | 0.13% |
53IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.12B | 0.12% |
54AHCO | ADAPTHEALTH CORP | Healthcare | $1.07B | 0.12% |
55AORT | ARTIVION INC | Healthcare | $947M | 0.10% |
56COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $775M | 0.08% |
57VREX | VAREX IMAGING CORP | Healthcare | $769M | 0.08% |
58GMRS | GMR SOLUTIONS INC | Healthcare | $754M | 0.08% |
59QDEL | QUIDELORTHO CORP | Healthcare | $729M | 0.08% |
60JANX | JANUX THERAPEUTICS INC | Healthcare | $703M | 0.08% |
61FLGT | FULGENT GENETICS INC | Healthcare | $694M | 0.08% |
62DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $663M | 0.07% |
63MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.06% |
64CTEV | CLARITEV CORP | Healthcare | $459M | 0.05% |
65ARVN | ARVINAS INC | Healthcare | $450M | 0.05% |
66AVTX | AVALO THERAPEUTICS INC | Healthcare | $445M | 0.05% |
67EMBC | EMBECTA CORP | Healthcare | $364M | 0.04% |
68MPLT | MAPLIGHT THERAPEUTICS INC | Healthcare | $328M | 0.04% |
69EIKN | EIKON THERAPEUTICS INC | Healthcare | $327M | 0.04% |
70EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.03% |
71EVMN | EVOMMUNE INC | Healthcare | $291M | 0.03% |
72OFIX | ORTHOFIX MEDICAL INC | Healthcare | $283M | 0.03% |
73QTTB | Q32 BIO INC | Healthcare | $264M | 0.03% |
74BIOA | BIOAGE LABS INC | Healthcare | $260M | 0.03% |
75ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.03% |
76RXST | RXSIGHT INC | Healthcare | $226M | 0.02% |
77AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.02% |
78TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.02% |
79KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.02% |
80RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.02% |
81ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.02% |
82OPRX | OPTIMIZERX CORP | Healthcare | $167M | 0.02% |
83STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.02% |
84INGN | INOGEN INC | Healthcare | $146M | 0.02% |
85RNA | ATRIUM THERAPEUTICS INC | Healthcare | $128M | 0.01% |
86SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $123M | 0.01% |
87IMUX | IMMUNIC INC | Healthcare | $106M | 0.01% |
88PARK | PARK DENTAL PARTNERS INC | Healthcare | $101M | 0.01% |
89RLYB | RALLYBIO CORP | Healthcare | $84M | 0.01% |
90VTVT | VTV THERAPEUTICS INC | Healthcare | $83M | 0.01% |
91GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.01% |
92XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.01% |
93ELOX | ELOXX PHARMACEUTICALS INC | Healthcare | $52M | 0.01% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $912.65B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 97% toward Large, 42% toward Growth. +9% unclassified (23 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 93 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T043645 rates=20261113T043645
Measured on the 2026-11 formation date across 93 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 30.8% | 12.7% |
| 3 yearsp.a. | 16.4% | -2.3% |
| 5 yearsp.a. | 9.6% | -0.1% |
| 10 yearsp.a. | 9.8% | -3.9% |
| Since inceptionp.a. | 11.6% | 3.7% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 31.2% | 10.2% |
| 2025 | 19.0% | 0.8% |
| 2024 | -4.3% | -15.4% |
| 2023 | -4.5% | -17.0% |
| 2022 | -1.4% | 18.0% |
| 2021 | 18.8% | -1.4% |
| 2020 | 13.9% | -7.7% |
| 2019 | 24.3% | 3.4% |
| 2018 | -3.3% | -12.8% |
| 2017 | 11.3% | -11.8% |
| 2016 | -18.3% | -8.4% |
| 2015 | 17.9% | 7.9% |
| 2014 | 35.8% | 10.1% |
| 2013 | 49.4% | -3.4% |
| 2012 | 16.0% | -5.3% |
| 2011 | 17.4% | 5.9% |
| 2010 | 11.2% | 3.6% |
| 2009 | 40.4% | 21.6% |
| 2008 | -42.4% | -26.4% |
| 2007 | 14.0% | 15.8% |
| 2006 | 7.0% | 6.8% |
| 2005 | 31.2% | 25.0% |
| 2004 | 25.6% | 32.5% |
| 2003 | 46.6% | 31.4% |
| 2002 | -22.9% | -5.9% |
| 2001 | 6.0% | 32.8% |
| 2000 | 77.5% | 43.1% |
| 1999 | -16.9% | -11.6% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare CashProd Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a CashProd signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.